Marc Lipsitch - Epidemiology

Author Information

Marc Lipsitch is a prominent researcher affiliated with the Departments of Epidemiology and Immunology and Infectious Diseases at the Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health in Boston, MA, USA. He is a leading figure in the field of epidemiology, with a focus on infectious diseases, and has made significant contributions to understanding and controlling disease dynamics.

Research Contributions

Marc Lipsitch's research spans various critical areas in epidemiology and infectious diseases. In 2022, his work addressed important topics such as antibiotic prescribing patterns, real-time surveillance of the SARS-CoV-2 epidemic, clinical outcomes of patients with the Omicron variant, and the implications of COVID-19 vaccination. His research not only contributes to the scientific understanding of these topics but also informs public health strategies and policies. His work has been instrumental in guiding vaccine prioritization and understanding the indirect protection offered by parental vaccination against SARS-CoV-2 infection.

Aliases

Marc Lipsitch is known by several aliases, including M Lipsitch, M. Lipsitch, and Mark Lipsitch. These variations are used interchangeably in different publications and databases.

Publication and Citation Metrics

Metric	Value
Citation Count	49,871
h-index	114
Paper Count	557

Publications:

Antibiotic prescribing across age groups in the Kaiser Permanente Northern California population in association with different diagnoses, and with influenza incidence, 2010-2018

DOI: 10.1017/s0950268822000371

Year: 2022

Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data

DOI: 10.1371/journal.pcbi.1009964

Year: 2022

Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California

DOI: 10.1101/2022.01.11.22269045

Year: 2022

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.

DOI: 10.1056/NEJMoa2201688

Year: 2022

Indirect protection of children from SARS-CoV-2 infection through parental vaccination

DOI: 10.1126/science.abm3087

Year: 2022

Identifying and alleviating bias due to differential depletion of susceptible people in post-marketing evaluations of COVID-19 vaccines

DOI: 10.1093/aje/kwac015

Year: 2022

Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study

DOI: 10.1136/bmj-2021-068414

Year: 2022

Excess COVID-19 associated deaths among the unvaccinated population >= 18 years old in the US, May 30 through December 4, 2021

DOI: 10.1101/2022.02.10.22270823

Year: 2022

Equitable COVID-19 vaccine prioritization: front-line workers or 65-74 year olds?

DOI: 10.1101/2022.02.03.22270414

Year: 2022

Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial – BCPP/Ya Tsie trial

DOI: 10.7554/eLife.72657

Year: 2022

What Role Do Laboratory Networks Play?

What is the Predictive Value?

What Role Does Globalization Play in Epidemiology?

What Role Do Institutions Play in Capacity Building?

What is a Global Health Network?

What Types of Studies Focus on Households?

What Are the Epidemiological Implications of Nutrition Labeling?

How can STEMI Networks be Improved?

How to Assess Data Reliability?

How Does the ECDC Contribute to Research?

Partnered Content Networks

Relevant Topics